1. Home
  2. NCRA vs DCOY Comparison

NCRA vs DCOY Comparison

Compare NCRA & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

HOLD

Current Price

$0.28

Market Cap

5.6M

ML Signal

HOLD

DCOY

Decoy Therapeutics Inc. Common Stock

N/A

Current Price

$7.60

Market Cap

4.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NCRA
DCOY
Founded
2002
N/A
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
4.7M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
NCRA
DCOY
Price
$0.28
$7.60
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$30.00
AVG Volume (30 Days)
114.5K
79.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.53
52 Week High
$2.40
$9.09

Technical Indicators

Market Signals
Indicator
NCRA
DCOY
Relative Strength Index (RSI) 33.41 83.76
Support Level N/A $0.61
Resistance Level $0.45 $9.09
Average True Range (ATR) 0.07 0.28
MACD 0.01 0.80
Stochastic Oscillator 12.00 81.42

Price Performance

Historical Comparison
NCRA
DCOY

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About DCOY Decoy Therapeutics Inc. Common Stock

Decoy Therapeutics Inc is a preclinical-stage biotechnology company developing peptide conjugate drug candidates using machine learning, artificial intelligence tools, and high-throughput synthesis techniques. The company's initial pipeline is focused on respiratory viruses and GI cancers.

Share on Social Networks: